Head, Carcinogen-DNA Interactions Section
National Cancer Institute, Bldg. 37, Rm 4032, NIH
37 Convent Drive
Bethesda, MD 20892-4255
I received an MSc in Oncology with Jim and Betty Miller in McArdle in 1964 after which I worked in the Pitot lab. I received a Ph.D. in Microbiology from Catholic University in 1977. I have worked in the National Cancer Institute since 1971. I pioneered antibody-based methodologies for determining chemical carcinogen-induced DNA damage in humans. Cell culture, animal models and human subjects have been employed to elucidate factors associated with human cancer risk. Information on DNA adduct processing in nuclear and mitochondrial DNA has been correlated with: tumorigenesis, clinical response, toxicity, and integrity of organelles. The carcinogens of intensive investigation include: the environmental polycyclic aromatic hydrocarbons (PAHs); the adjuvant chemotherapeutic drug tamoxifen (TAM); and the antiretroviral nucleoside reverse transcriptase inhibitors (NRTIs) used for therapy of human immunodeficiency virus type 1 (HIV-1). Areas of Expertise - 1) chemical carcinogenesis 2) carcinogen-DNA damage 3) biomarker dosimetry 4) molecular epidemiology 5) mitochondrial toxicology 6) transplacental exposure.